Clinical Trials List
2020-09-01 - 2026-12-31
Phase II
Not yet recruiting1
Recruiting3
Terminated3
A Multicenter, Open-label, Single-arm, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 and Are Continuing ONO-4538 Treatment
-
Sponsor
Ono Pharmaceutical Co., Ltd.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- YEN-HAN TSENG Division of Thoracic Medicine
- Chao-Hua Chiu 無
- Chia-I Shen Division of Thoracic Medicine
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
- Nai-Jung Chiang 未分科
- 蘇勇曄 Division of Hematology & Oncology
- Kwang-Yu Chang Division of Hematology & Oncology
- 姜乃榕 無
- Shang-Hung Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wang Yao-Kuang Digestive System Department
The Actual Total Number of Participants Enrolled
0 Completed
The Actual Total Number of Participants Enrolled
0 Completed
Co-Principal Investigator
- 林正耀 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chien-Ying Liu Division of Hematology & Oncology
- 枋岳甫 Division of Thoracic Medicine
- Chih-Hung Chen Division of General Internal Medicine
- Ping-Chih Hsu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
1) Sex: Male and female
2) Age (at the time of consent): 20 years and older
3) Participant who is eligible for ONO-4538 treatment as per the Parent Study, and/or investigator-assessed clinical benefit
4) Participant who is being treated with ONO-4538 as monotherapy in the Parent Study
5) Women of childbearing potential (WOCBP) must agree to use a double-barrier contraceptive method and avoid breastfeeding during the stipulated period
6) Men must agree to use a contraceptive method during the stipulated period
Exclusion Criteria
1) Participant judged to be incapable of providing consent for reasons such as concurrent dementia
2) Participant judged by the investigator to be inappropriate as participants of this study
The Estimated Number of Participants
-
Taiwan
9 participants
-
Global
16 participants
